BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C

Chronic Hepatitis C Clinical Trial

— BIP48II/III  

Official title:

Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C: Randomized, Multicentric Study With Blinded Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01623336
• Other study ID #: 11/0468
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: June 13, 2012
• Last updated: June 15, 2012
• Start date: January 2012
• Est. completion date: December 2016

Study information

• Verified date: November 2011
• Source: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
• Contact: Valeria Lucia de S. Gil, ASCLIN
• Phone: 552138827199
• Email: valeria.lucia[@]bio.fiocruz.br
• Is FDA regulated: No
• Health authority: Brazil: The Immunobiological Technology Institute (BIO-Manguinhos)/Oswaldo Cruz Foundation
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to demonstrate the noninferiority of BIP48 (48 kDa peginterferon alfa-2b) compared to Pegasys ® (40 kDa peginterferon alfa-2a) associated with ribavirin, in naive patients with chronic hepatitis C.

Description:

The study will be an open, multicenter, randomized, controlled phase II - III trial. Patients (n = 740) will be randomized (1:1) to receive BIP48 (peginterferon alfa-2b 48kDa) or Pegasys ® (peginterferon alfa-2a 40kDa) 180 micrograms ,subcutaneously,once a week,associated with ribavirin at a dose 1000-1250 mg, orally, daily. For genotype 1 treatment time will be 48 to 72 weeks and for genotypes 2 and 3, 24 to 48 weeks. The study's population will be naive patients, of both sex, between 18 and 70 years old, with chronic hepatitis C (HCV), genotypes 1, 2 or 3, from 18 to 25 Brazilian research centers. Diagnostic criteria will be as followed: positive anti-HCV and qualitative PCR, liver biopsy showing any degree of fibrosis and at least mild inflammatory activity, performed in the last 24 months. The interruption Criteria will be: no partial virological response at 12 weeks and positive quantitative PCR at week 24.The primary outcome will be the rate of sustained virologic response and the secondary endpoints will be the quality of life during treatment, frequency of adverse events and cost-effectiveness. As a substudy, will be performed a comparative assessment in 24 patients, evaluating viral kinetics, pharmacokinetics and pharmacodynamics of repeated doses of both alfapeginterferons .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 740
• Est. completion date: December 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. anti-HCV positive;

2. viral load of HCV positive;

3. viral genotypes 1, 2 or 3;

4. the absence of previous treatment for chronic hepatitis C;

5. liver biopsy performed in the last 36 months classified by Metavir score as at least A1, with any degree of fibrosis ;

6. age from 18 to 70 years old;

7. hemoglobin greater than 11 g / dl;

8. platelet count higher than 75.000/mm3;

9. neutrophils higher than 1.500/mm3;

10. use of, at least two contraceptive methods during treatment and up to 36 weeks after the last dose of study medication (for male or female subjects in fertile age );

11. concordance and signing of the informed consent.

Exclusion Criteria:

1. decompensated cirrhosis (Child-Pugh score> 6);

2. history of bleeding gastroesophageal varices;

3. hemoglobinopathies;

4. hepatocellular carcinoma;

5. co-infection with HIV or HBV;

6. other coexisting chronic liver disease, as autoimmune hepatitis, Wilson disease, hemochromatosis, chronic obstructive cholestatic disease or autoimmune disease, alcoholic liver disease;

7. malignancies except basal cell carcinoma in situ or cervix carcinoma;

8. systemic autoimmune diseases, except compensated autoimmune thyroid diseases ;

9. uncontrolled seizures;

10. primary immunodeficiencies;

11. myelosuppression;

12. coagulation disorders;

13. thrombophilias;

14. thrombopathy ;

15. decompensated heart failure;

16. chronic renal failure;

17. diagnosis of other comorbidity that would compromise the subject's participation in the research study as judged by the investigator (eg, neuropsychiatric diseases, systemic infection or antibiotic use within 4 weeks, decompensated diabetes mellitus, ischemic heart disease, heart failure, respiratory or renal or uncontrolled hypertension);

18. prior organ transplantation, except cornea;

19. alcohol consumption exceeding 20g/day for women and 40g/dia for men during the past six months;

20. use of illicit drugs in the previous six months;

21. use of immunosuppressive agents during the previous six months;

22. pregnancy or lactation;

23. male research subjects whose sexual partner is pregnant;

24. previous treatment with IFN or ribavirin in the last 6 months prior to inclusion;

25. subjects with hypersensibility to IFN alpha and / or any of its components;

26. subjects with hypersensibility to ribavirin and / or any of its ingredients;

27. participation in another clinical study in the last 12 months

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis C
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• BIP 48 (Peginterferon alfa 2b 48kDA)
BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
• Peginterferon alfa 2a 40kDA
Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
• BIP 48 (Peginterferon alfa 2b 48kDA)
Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.

Locations

Country	Name	City	State
Brazil	Ufrgs/Hcpa	Porto Alegre	Rio Grande do Sul

Sponsors (2)

Lead Sponsor	Collaborator
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)	Hospital de Clinicas de Porto Alegre

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.		HCV PCR will be measured at 24 weeks after the end of therapy (week 48 for genotypes 2 and 3 and week 72 for genotype 1)	No
Secondary	Frequency of adverse events	Blood tests included: ALT, AST, Creatinine and complete blood count. Anti-interferon immunoglobulin and thyroid-stimulating hormone (TSH) will be measured in the weeks 12, 24, 36, 48, 60 and 72 of the study.	Clinical exam, blood tests and immunogenicity evaluation will be done twice monthly, in the first month, and then monthly until the end of treatment( week 24 for genotypes 2 and 3 and week 48 for genotype 1).	Yes
Secondary	Virologic response at the end of treatment	Viral load will be measured by quantitative PCR at the end of treatment.	Viral load will be measured at the end of treatment (week 24 for genotypes 2 and 3 and week 48 for genotype 1)	No